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Summary A system for the prediction of clinical response in acute myelocytic leukaemia (AML), based on
inhibition of growth of colony forming cells (CFC) was studied. If the product of initial drug concentration
and time of exposure (C xT) was constant, the response to adriamycin (Adr) was constant, at T values
<48h. No constancy of response to the phase-specific agents cytosine arabinoside (Ara-C) and 6-thioguanine
(6TG) was demonstrated with constant C xT (T value range 0.25-48h). Hence in the predictive test, a 1 h
incubation with Adr was employed whilst a continuous exposure to Ara-C and 6TG, with these drugs
incorporated in the agar medium, was used. The in vitro sensitivity to Adr, Ara-C and 6TG of 19 AML
patients and the predictive value of several parameters of sensitivity were evaluated. 6TG sensitivity was not
useful for prediction of remission. Adr sensitivity in vitro made a greater contribution to prediction of
remission than did Ara-C sensitivity. Seventy-nine percent of patients were correctly classified if Adr data
alone were considered. A multivariate function including Adr and Ara-C results was obtained which resulted
in 84% of patients correctly classified as sensitive or resistant to the agents received in remission-induction
therapy.
AML should provide a suitable model for
evaluation of the use of a colony inhibition assay
(Salmon et al., 1978, 1980) to predict clinical
response to chemotherapy, because of the ease of
sample collection, the lack of requirement for
enzyme digestion to obtain single cell suspensions, a
high percentage of patients whose tumour cells
form colonies in semi-solid media and the
significant number of patients who achieve
complete remission. Guidelines for determining the
assay parameters of C (initial drug concentration)
and T (duration of exposure), and for optimal
analysis of the data obtained require resolution.
Efforts to approximate to the in vivo situation
have led to the design of in vitro assays based on
the pharmacokinetic parameters of the peak plasma
concentration and the product of plasma
concentration and time of exposure (C xT),
determined in patients receiving the appropriate
drugs. The in vitro concentration at the
commencement of the incubation (C) has been
derived from the plasma C xT value, the T value
being constant for each agent investigated. Most
investigators have used an incubation of one hour's
duration (Preisler, 1980; Park et al., 1980).
In many instances a constant biological response
results from a constant C x T, irrespective of the
individual values of C and T (Mellett, 1974).
However, drugs which act specifically on S-phase
cells for example, will only be capable of acting on
that fraction of cells which enter S-phase during the
1 h exposure.
In this study, in order to evaluate the importance
of T in the in vitro system, the constancy of
response to a given C x T value with increasing
values of T was investigated for adriamycin (Adr),
cytosine arabinoside (Ara-C) and 6-thioguanine
(6TG).
Having determined appropriate values of C and
T for each drug, drug sensitivity profiles for a series
of AML patients were obtained and then compared
with the clinical response. A model was constructed
for recognising sensitive and resistant patients using
data obtained in these assays.
Materials and methods
Patients
Samples from 38 patients with a diagnosis of AML
admitted to the Royal Brisbane Hospital or Royal
Children's Hospital, Brisbane in 1981 and 1982
were studied. The clinical characteristics of those
patients whose cells were studied in the predictive
assay are listed in Table I. Patients received
induction treatment with either Adr, Ara-C,
vincristine and prednisone administered as the
ADOAP regimen (Bodey & Rodriguez, 1978) or
6TG, Ara-C and daunorubicin (Dnr) administered
as the TAD regimen (Gale & Cline, 1977).
Complete remission was defined as disappearance
of evidence of disease; normal bone marrow (blasts
<5%) and normal peripheral blood smear. Patients
who did not receive chemotherapy were evaluated
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Table I Characteristics ofAML patients*
Patient
No. Sex/Age Sample Tested Status
1 M/23 bone marrow Untreated
2 M/27 bone marrow Relapse
3 M/20 peripheral blood Untreated
4 F/26 bone marrow Untreated
5 F/18 peripheral blood Untreated
6 M/ 8 peripheral blood Untreated
7 F/27 bone marrow Untreated
8 F/ 9 peripheral blood Untreated
9 M/ 5 peripheral blood Untreated
10 M/41 peripheral blood Untreated
11 F/58 peripheral blood Untreated
12 M/ 2 peripheral blood Untreated
13 M/64 bone marrow Relapse
14 F/31 peripheral blood Untreated
15* M/28 peripheral blood Untreated
16 M/25 peripheral blood Relapse
17 M/30 peripheral blood Untreated
18 M/27 bone marrow Untreated
19 M/19 bone marrow Untreated
*All patients had acute myelocytic leukaemia, with the
exception ofpatient no. 15 (acute monocytic leukaemia).
for clonogenicity but not evaluated in the predictive
assay. Patients who entered complete remission
after one or two courses of treatment were
classified as complete responders (CR), whilst those
who did not were classified according to the criteria
of Epstein & Preisler (1981). Type I and Type II
failures were classified as non-responders (NR).
Cellpreparation and storage
Heparinised bone marrow and peripheral blood
were obtained from patients with AML as part of
the diagnostic procedure at presentation or relapse
prior to treatment. Diluted peripheral blood (1:1
with RPMI 1640) was centrifuged on Ficoll-Paque
(specific gravity, 1.077) (Pharmacia, Uppsala) at
400xg for 40min, interface cells were collected,
washed twice and resuspended in RPMI 1640
medium with 10% foetal calf serum (FCS). Bone
marrow was centrifuged once at 150xg for 10min
and also resuspended in RPMI 1640 medium with
10% FCS. The fresh samples were plated in agar to
determine cloning efficiency. Remaining cells were
suspended in RPMI 1640 with 5% dimethyl-
sulphoxide (DMSO) and 15% FCS, frozen and
stored in liquid nitrogen. When required they were
thawed rapidly to the point of phase-transition,
then kept on ice, diluted slowly and washed with
ice cold RPMI with 10% FCS.
Colony-forming assay
The method used is a modification of standard
methods for growing AML colonies (Metcalf,
1977). The agar medium consisted of 1 part bacto-
agar (Difco) at 0.8%. This resulted in a final agar
concentration of 0.36%. This concentration was
chosen instead of the 0.3% used by Preisler (1980)
and Park et al. (1980) since 6/22 AML samples
assayed exhibited increased cloning efficiency (CE)
if the agar concentration was increased (Table II).
Table II Effect of agar concentration on cloning
efficiency (CE) of AML bone marrow of 6 individual
patients
CE (%) (±s.d.)
Final agar concentration (% w/v)
0.27 0.32 0.36 0.41
0.038+0.002 0.10+0.02* 0.23+0.02* 0.29+0.03*
0.60 +0.09 0.58+0.16 2.04+0.20* 1.96+0.01*
0.06 +0.02 0.05+0.04 3.22+0.68* 3.10+0.22*
0.00 +0.00 6.80+0.44 8.46+0.80* 9.22+0.62*
0.00 +0.00 0.00+0.00 15.18+0.76* 17.18+1.51*
0.00 +0.00 0.17+0.02* 0.43+0.01* 0.29+0.02*
*Denotes CE significantly different (P<0.01) from CE
at 0.27% agar.
Graded agar concentrations showed that this was
due to decreased dispersion of proliferating cells
allowing discrete colonies to be formed. The
cloning efficiency ofother samples assayed exhibited
no significant change with increased agar concen-
tration. The agar was boiled for 2min then cooled
to 37°C and mixed with 1 part hypertonic medium
warmed to 370C. The hypertonic medium used was
a modification of that described by Sheridan &
Simmons (1981). This consisted of: FCS, 33%;
Dulbecco's modified Eagle's medium (H-16, Gibco),
lOg in 215ml water supplemented with 0.575ml
penicillin G at 2x 10 Uml-', and 0.375ml
streptomycin at 2x lO5Uml-1, 29%; NaHCO3,
28mgml', 10%; rat erythrocyte lysate (Bertoncello
& Bradley, 1981), 8.0%; HEPES buffer, 6mgml-P
(pH 7.3), 4.0%; insulin 100Uml-1, 0.80%; L-
asparaginase, 6.6mgml-1, 0.40%; hydrocortisone,
0.18mgml-1, 0.020%; and 14% water. The medium
was sterilised by 0.45p-membrane filtration. Cells
were suspended in the agar medium at 370C to give
a final concentration of 5 x 103, 5 x 104 or
5 x 10 ml- . The cell concentration for all
experiments was adjusted to result in 30-100
colonies per control plate using results of
preliminary platings. Aliquots (1 ml) of this
suspension were plated in triplicate orCHEMOSENSITIVITY IN AML 561
quadruplicate (if cell numbers allowed) in 35mm
Petri dishes containing 100 l of human placental
conditioned medium (HPCM) (Burgess et al., 1977).
Plates were incubated at 37°C in an environment of
5% 02, 5% C02, 90% N2 and 100% humidity.
Colonies of >40 cells were scored at 7 days.
Results were expressed as cloning efficiency (the
number of colonies scored expressed as percentage
of the number of cells plated).
Calculation ofC x T values
The C x T values of Adr and Ara-C used were lx,
0.3x and O.lx the values calculated from published
pharmacokinetic data, being 3pig.hml-' for a dose
of 60mgm 2 Adr (Harris & Gross, 1975) and
9pug.hml-t for a 7 day infusion of Ara-C at
70mgm2 (Alberts, 1979). These values were used
in both the C x T experiments and the predictive
assay.
A CxT of 70,ug.hml-1 for a single i.v.
administration of 6TG used at 135mgm-2 (LePage
& Whitecar, 1971) determined the highest value of
6TG used in the C x T experiment. A value of
15pg.hml-' was calculated to result from an oral
6TG dose of 2.5mgkg-1 per 12h x 7 days (LePage
& Whitecar, 1971; Dooley & Maddocks, 1980). As
this was the dose and means of administration used
in the patients studied, the value of 15ijg.hml-
was used in the predictive assay.
C x T experiments
A cell suspension in RPMI 1640 with 10% FCS
and 10% HPCM was prepared, and 900ul aliquots
were pipetted into 24-well tissue culture trays
(16mm well diameter). It had been shown
previously that cells from the 5 patients studied
(patients 1, 4, 8, 10 and 11) would proliferate in
liquid culture for at least 1 week in these
conditions. At each time point 100up of drug
dissolved in RPMI 1640 at lOx the final
concentration, or RPMI 1640 alone in the case of
the controls, was added to the wells. The plates
were incubated for 48h with additions at 0, 24, 44,
47 and 47.75h thus incubations with antineoplastic
agents were of 48, 24, 4, 1 and 0.25h duration.
Three concentrations of Adr and Ara-C were
studied at each time point. The 5 concentrations of
6TG studied were calculated from values obtained
from both high dose and low dose therapy. Stock
solutions were prepared by serial dilution on Day 1
of these experiments and stored frozen at -70°C
until use.
After 48 h incubation the cells were washed twice
with 5ml of RPMI 1640 and finally resuspended in
4ml of agar medium for plating in triplicate. The
area under each dose-response curve plotted on a
linear scale was calculated (Alberts et al., 1981;
Moon et al., 1981. This area, expressed as a
percentage of no response (AUC), was calculated
and used as a measure of the magnitude of
response.
Predictive assay
Peripheral blood or bone marrow cells were
incubated with or without Adr at 3.0, 0.9 or
0.3 ugml-1 for 1 h, washed twice with 5ml of
RPMI 1640 and plated. The effects of Ara-C and
6TG were studied with the drugs incorporated in
the agar medium for the 7-day incubation. The
final concentrations of Ara-C were 55, 16.5 and
5.5ngml-P. The final concentrations of 6TG used
were 90, 27 and 9ngml-'. The highest
concentration in each case is the calculated plasma
CxT value divided by 168h (7 days). Where both
peripheral blood and bone marrow were available
from the same patient, studies found no significant
difference in drug sensitivity between peripheral
blood and bone marrow samples.
Statistical analysis
Analysis of variance was performed using the
Scheffe test and the variance ratio method.
Discriminant analysis was used to determine points
of discrimination for single agents in order to
classify patients as sensitive or resistant on the basis
of results obtained in the predictive assay.
Multivariate analysis using AUC data from all
patients was used to determine a discriminant
function and the probability of selecting the correct
group for individual patients. All the above
statistical analysis was carried out using SPSS
programs.
Results
Effect of varying duration of exposure (T) whilst
maintaining a constant C x T value
Five values of T were used. A dose response curve
of colony formation as a function of C was
obtained at each of the 5 values of T. A range of 3
concentrations of Adr and Ara-C, and 5
concentrations of 6TG, were used to obtain the
dose response curves, As T became progressively
larger C was decreased proportionally, hence the
C xT values studied (3 for Adr and Ara-C and 5
for 6TG) were constant throughout the
experiments.
Figure 1 shows the results of these experiments
obtained for Patient 1. This experiment was562 M.G. LIHOU & P.J. SMITH
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Figure 1 Inhibition of colony formation (patient 1) in
response to Adr, Ara-C and 6TG. For each agent 5
dose-response curves were obtained using 5 values of T
(0.25, 1, 4, 24 and 48h). The concentration range at
each time point was such that the C x T values stiidied
were constant for each agent at each of the 5 time-
points. Each point represents the mean (s.d. < 10%) of
triplicate determinations.
repeated for Patients 4, 8, 10 and 11. The response
to Adr (Figure 1) changed little as T increased for
each constant C xT value. The magnitude of
response to Ara-C and 6TG, however, increased
with increasing T values despite the consequent
decrease in concentration of these agents. Similar
results were obtained for all 5 patients. As a
measure of the magnitude of the response, for each
of the 15 dose response curves obtained per patient
(over the range of C x T values studied), the AUC
was calculated (Alberts et al., 1981; Moon et al.,
1981). The relationship between the magnitude of
response obtained and time of exposure, for each
patient is represented in Figure 2. The response to
Adr was constant with time, the only significant
source of variation being due to patient differences
(P<0.01). One patient (Patient 10) appeared less
sensitive to Adr as concentration decreased and
time of exposure increased beyond 4h. With the
phase-specific agents (Ara-C and 6TG), increasing
T significantly increased the magnitude of response
to these drugs (P<0.01 for Ara-C and P<0.001 for
6TG). This apparent increase in sensitivity with
increasing T occurs despite the proportional
decrease in drug concentration.
Since the response to C x T for Adr was constant
at various T values at least up to 4h, it was decided
that a 1 h incubation with Adr was suitable for use
in the in vitro predictive assay. For the phase-
specific drugs, since the response to C x T was not
constant with variable T values, it was decided that
the value of T should approximate to the duration
of the exposure to these drugs during treatment.
Incorporation of the drugs in the agar medium
allowed a 7-day continuous exposure.
Patients assessable in predictive assay
Over a 2-year period a total of 38 AML samples
was received: 26 (or 68%) of these formed colonies
in agar when 0.36% agar was used. Of these 26,
five were excluded from assessment in the predictive
assay (4 were not treated, 1 died prior to
treatment). Of the remaining 21 patients insufficient
cells were held in storage to permit performance of
the predictive assay on a further 2 samples. The in
vitro chemosensitivity of the remaining 19 patients
(Table I) was evaluated. Eleven of these patients
entered complete remission and were classified as
CR and 8 were Type I or Type II failures and
classified as NR. There were no Type III, Type IV
or Type V failures in the group of patients whose
AML samples formed colonies.
Predictive Assay
Dose response curves (at the T values indicated
above) to Adr and Ara-C were obtained for all of
the 19 patients. Dose response curves to 6TG were
obtained only for the 12 patients on the TAD
regimen. Results given in Table III were analysed
by the following methods. Linear discriminant
analysis was used to determine points of
discrimination using the following measures of
response: (1) AUC expressed as a percentage of no
response, (2) percentage survival at 0.lx plasma
C xT and (3) percentage control at plasma C x T.
These points were determined for each agent
separately. Also evaluated was the predictive value
of the criteria used by Meyskens et al. (1981), i.e.
(4) a reduction in CFU survival to below 38% at
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Figure 2 Response of colony-forming cells from patients 1, 4, 8, 10 and 11 to Adr, Ara-C and 6TG after
different lengths of exposure to these agents. The experiment depicted in Figure 1 was repeated with cells
from patients 4, 8, 10 and 11. The area under each dose-response curve (AUC) was calculated and plotted
against duration of exposure (s.d. for individual points was < 10%).
in Table IV. Additionally, a multivariate
discriminant analysis of the AUC obtained for Adr
and Ara-C was undertaken (Table IV).
When 6TG results were analysed the range of
AUC values for the 9 CR patients was from 28%
to 101% of no response (mean 74%). The values
obtained for the 3 NR patients were in the middle
of this range at 64%, 67% and 77% (mean 69%).
Likewise, when the values of percentage survival at
0.lx plasma C x T were considered there was no
discrimination between the CR and NR groups. At
the plasma C x T a point of discrimination of 51%
was determined which resulted in 42% of patients
being correctly classified. A cut-off point of 38%
survival at 0.lx plasma C x T resulted in 33% of
patients being correctly classified. The 6TG results
were not included in the multivariate analysis due
to the poor discrimination between the groups by
the data. The small number of patients resistant to
the TAD protocol available for study may have
contributed to this problem.
The Kendall rank correlation coefficients
indicated no significant correlation between Adr
and Ara-C results either for AUC (correlation
coefficient =0.2), percentage survival at 0. lx C x T
(correlation coefficient =0.08) or percentage
survival at C x T (correlation coefficient =0.3).
For Adr and Ara-C the percentage survival at
0. lx plasma C x T was a better discriminator than
the percentage survival at plasma C xT. The least
accurate predictions were obtained when a point of
discrimination of 38% survival at 0.lx plasma
C x T was used (Table IV).
The standardized canonical discriminant function
coefficients were 0.90 for Adr and 0.36 for Ara-C,
indicating that the AUC for Adr is 2.5 times
more useful for prediction of response than is the
Ara-C AUC. This is also suggested by the
univariate analysis in which irrespective of the
variable measured (AUC, percentage survival at 0. lx
plasma C x T etc.), more correct results are
obtained when patients are classified according to
their response to Adr rather than Ara-C.
As would be expected, the multivariate function
(-1.71+0.05 Adr AUC+0.03 Ara-C AUC) was
the best discriminator of those listed in Table IV.
The probability of selecting the correct group, given
an individual patient's results, was also calculated
for the multivariate function. Because there were
few very high or very low values, only 6/19 values
had a probability >0.80 of being selected for the
correct group. The discriminant function obtained
100% true positive results, 63% true negative
results and a total of 84% of patients tested were
correctly classified as sensitive or resistant. Using
Adr results alone (either AUC or percentage
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Table III Clinical and in vitro response
In vitro response
% Control % Control
Clinical Patient AUC at 0.1 atplasma
Agent response Treatment* no. (% no response) plasma C x T C x T
Adr CR ADOAP 4 22 57 0
Adr CR ADOAP 8 18 51 0
Adr CR TAD 6 8 22 0
Adr CR TAD 10 9 7 1
Adr CR TAD 12 5 0 0
Adr CR TAD 13 23 27 0
Adr CR TAD 14 33 98 14
Adr CR TAD 15 25 38 6
Adr CR TAD 16 15 54 0
Adr CR TAD 17 12 32 0
Adr CR TAD 18 17 58 0
Adr NR ADOAP 3 39 72 1
Adr NR ADOAP 5 63 82 31
Adr NR ADOAP 7 103 110 75
Adr NR ADOAP 9 45 89 11
Adr NR ADOAP 19 8 22 0
Adr NR TAD 1 20 56 0
Adr NR TAD 2 10 15 2
Adr NR TAD 11 26 62 0
Ara-C CR ADOAP 4 12 14 0
Ara-C CR ADOAP 8 27 78 1
Ara-C CR TAD 6 15 32 0
Ara-C CR TAD 10 22 51 0
Ara-C CR TAD 12 7 13 0
Ara-C CR TAD 13 8 23 0
Ara-C CR TAD 14 5 2 0
Ara-C CR TAD 15 25 52 0
Ara-C CR TAD 16 26 61 3
Ara-C CR TAD 17 7 97 0
Ara-C CR TAD 18 18 38 0
Ara-C NR ADOAP 3 6 3 0
Ara-C NR ADOAP 5 64 76 47
Ara-C NR ADOAP 7 10 22 0
Ara-C NR ADOAP 9 28 61 0
Ara-C NR ADOAP 19 15 32 0
Ara-C NR TAD 1 26 46 1
Ara-C NR TAD 2 5 2 0
Ara-C NR TAD 11 16 27 1
6TG CR TAD 6 76 90 60
6TG CR TAD 10 85 79 80
6TG CR TAD 12 101 85 89
6TG CR TAD 13 28 36 1
6TG CR TAD 14 89 47 54
6TG CR TAD 15 64 96 36
6TG CR TAD 16 72 89 57
6TG CR TAD 17 71 97 24
6TG CR TAD 18 84 85 78
6TG NR TAD 1 64 56 65
6TG NR TAD 2 77 103 21
6TG NR TAD 11 67 68 69
CR=complete responders; NR=non responders.
*ADOAP =Adr, Ara-C, vincristine & predinisone; TAD =6TG; Ara-C &
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Table IV Analysis of association between clinical and in vitro results
% truepositive % true negative % correctly
results results classified
Method (n =11) (n=8) (n=19)
Univariate analysis:
Cut-off
Criteria Agent Point %
AUC Adr 30 91 63 79
(% no response) Ara-C 18 64 50 58
% control at Adr 56 73 88 79
0.1 plasma C x T Ara-C 37 55 50 53
% control at Adr 9 91 38 68
plasma C x T Ara-C 3 100 13 63
% control at Adr 38 45 88 63




(% no response) 100 63 84
Discussion
Results of previous studies (Preisler, 1980; Park et
al., 1980) have suggested that colony-inhibition
assays may discriminate between sensitive and
resistant AML patients. Preisler (1980)
demonstrated discrimination between 10 resistant
and 10 sensitive patients as groups without
developing a formula for predicting response for
individual patients. Park et al. (1980), studying 9
patients, could distinguish between sensitive and
resistant patients with a double assay using
patients' blast cells and control bone marrow.
However guidelines for the in vitro evaluation of
agents common to AML protocols in these assays
have not been established. For example, the
proportion of cells entering S-phase during
exposure to S-phase specific agents should
determine the degree of cytotoxicity achievable. It
has been suggested, therefore, that phase-specific
agents such as Ara-C and 6TG be used
incorporated in the agar medium (Alberts et al.,
1981; Moon et al., 1981; McCullouch et al., 1981,
1982). The values of concentration and duration of
exposure for phase-specific agents which are
relevant for use in the predictive assay system have
not been determined, although Alberts et al. (1981)
have recommended use of concentrations 1/200 to
1/300 of the 1 h exposure concentration. In several
studies a comparison of short-term and long-term
incubation of cells with different agents has been
made. Wu et al. (1982) found a dose dependent
decrease in colony formation of Raji lymphoma
cells after a 1 h exposure to Adr, actinomycin-D,
bleomycin, mitomycin C, vincristine and cis-
platinum with augmentation of the response after
continuous exposure. The antimetabolites Ara-C,
methotrexate and 5-fluorouracil exhibited no
suppressive effects on colony formation with a 1 h
exposure but marked toxicity if the exposure was
continuous. Eicholtz & Trott (1980) studied the
interdependence of exposure time and methotrexate
concentration using Chinese hamster, HeLa and
HAK cells. Their results indicated that duration of
exposure to this phase-specific agent is the
dominant factor determining cell survival. These
reports of the inhibitory effect of increasing T on
colony formation have measured changes in
response over a set range of concentrations, but
have not directly addressed the question of how
response is affected when C x T is constant and T is
increased. They do, however, suggest than in an in
vitro predictive assay, the value of T may be
important for accurate prediction of the in vivo
response.
The C x T experiments were undertaken to
determine how closely T in the in vitro predictive
assay would approximate to the in vivo situation.
The response to Ara-C or 6TG continued to
increase as T increased from 0.25 to 48h. There
was no indication of a plateau of response being
reached despite the much lower concentrations
present in the 24 and 48h incubations. Exposure
over periods >48h was not investigated in liquid566 M.G. LIHOU & P.J. SMITH
culture due to the possible complicating effects of
cellular proliferation. Although the two experiments
are not directly comparable the response after 7
days continuous exposure to Ara-C in the agar for
Patients 1, 8 and 11 was greater than after 48h in
liquid culture. For both Ara-C and 6TG the
ranking of patients from most sensitive to most
resistant differed at different T values. As no simple
pattern emerged from these results, and since a 1 h
incubation with either Ara-C or 6TG at the
determined plasma C x T resulted in little inhibition
of colony formation, it was decided that the value
of T in in vitro assays using phase-specific agents
should approximate as closely as possible to the
duration of exposure to the drug in vivo. This is
relatively simple for Ara-C and 6TG patient
samples in our study as the 7 day period of
administration can be mimicked by a continuous
exposure in the agar. However periods of
incubation between -4h and 7 days and >7 days
present technical problems. AML cells cannot be
kept for extended periods in liquid culture and even
if this were possible proliferation of the more
resistant cells in a heterogeneous population would
complicate calculations of the initial proportion of
cells sensitive to the agent.
The greater contribution to prediction of
remission was made by Adr results rather than
Ara-C results. Using Adr results alone, 79% of
patients could be correctly classified. Adr sensitivity
in this system appears to be useful for predicting
response to anthracyclines, since 12/19 patients
received Dnr and not Adr. Preisler (1980) found
sensitivity to the anthracycline Dnr more highly
correlated with treatment outcome than sensitivity
to Ara-C (both 1h exposures) and suggested that
this may indicate the relative contribution each
agent makes to remission induction. He was not
able to distinguish between Ara-C sensitive and
resistant patients on colony inhibition data alone
due to overlapping values, but found when
sensitivity was related to the number of cells in S-
phase (as measured by [3H]-dT suicide indices) a
distinction could be made between sensitive and
resistant patients. It may be that continuous
incubation at low Ara-C concentrations measures
not only the cytocidal effect of the agent on S-
phase cells, but also a reversible cytostatic effect
which results in a GI/S block (Epstein & Preisler,
1981; Burgayne, 1974). Another explanation for the
poor predictive value of the Ara-C results is the
marked patient-to-patient variation in pharmaco-
kinetic parameters for Ara-C compared with Adr
pharmacokinetics.
These results are in contrast with the results of
McCullough e-t al. (1982) who in assessing the
contribution of blast cell properties to outcome
variation in AML, found that sensitivity to Ara-C
(continuous exposure) but not Adr (Omin
exposure), as measured by D1o values, contributed
to remission induction when considered in
univariate analysis. The median D1o value (60
trials) for Adr was at a CxT of O0.7yg.hml-1
and within the range of values tested by us, but the
median DI10 for Ara-C (61 trials) was
approximately 0.6jpgml-F for 5-7 days or a factor
of 10 higher than the highest C xT tested in our
system. Since the majority of patients tested in our
study (13/19) exhibited complete inhibition of
colony formation at 55ngml-1 it is difficult to
compare the two sets of data. However, the culture
system of McCullouch et al. (1982) uses methyl-
cellulose rather than agar. This may indicate a
difference in the availability of Ara-C to the cells in
the two different matrices.
The 6TG results were not useful for
discriminating between sensitive and resistant
patients. Inhibition of colony formation was
minimal for most patients when tested at the
calculated plasma C x T. Since 6TG has been a
useful addition to remission induction protocols for
AML (Gale & Cline, 1977), a greater inhibition of
colony formation would have been expected.
Whilst guidelines for analysis of results obtained
in these colony inhibition assays have been
suggested by others, no agreement has been reached
on the best method for analysis of the data. The
84% of patients correctly classified by the best
method tested in our study is similar to results
obtained by Park et al. (1980) for acute
nonlymphocytic leukaemia (80%), Salmon et al.
(1980) (89%) and Moon et al. (1981) (78%). The
latter two studies tested samples from ovarian
cancer, myeloma and melanoma patients. In our
study as well as that of Park et al. (1980) the true
positive rate was higher than the true negative rate,
whereas in the studies of Salmon et al. (1980) and
Moon et al. (1981), the opposite was the case. This
may be expected due to the higher proportion of
CRs obtained in the AML groups. We found as did
Salmon et al. (1980), and Moon et al. (1981) that
the percentage survival of 0.lx plasma C x T was a
better discriminator than the percentage survival at
the plasma C x T. The cut-off point of 38%
(Meyskens et al., 1981), however, was not as low as
points of discrimination determined in our study by
discriminant analysis and did not result in as many
correct classifications.
Although attempts were made to choose assay
parameters (C and T) relevant to the in vivo
situation, since most in vitro results were neither
very high nor very low, the probability of selecting
the correct group for an individual patient is lower
than in the in vitro/in vivo association figures might
suggest, i.e. although 84% of patients were
correctly classified, only 6/19 patients wereCHEMOSENSITIVITY IN AML 567
classified with >80% confidence. To obtain greater
discrimination between the CR and NR groups,
clarification of the optimal conditions for exposure
to Ara-C and 6TG in the predictive assay is
necessary. For patients receiving TAD, use of the
agents Adr, Ara-C and 6TG in appropriate
combination in vitro should be explored as a means
of more accurately predicting the clinical response.
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